Latin America Liver Cancer Market - Segmented by type, technology, end-user, and geography (2016 - 2021)

  • ID: 3784833
  • Report
  • Region: America, America (exc North), Latin America
  • 91 pages
  • Mordor Intelligence
1 of 4


  • 4SC AG
  • Alnylam Pharmaceuticals
  • ArQule Inc.
  • Bayer Schering Pharma AG
  • F Hoffmann la- Roche
  • ImClone Systems Inc.
  • MORE
Analysts forecast the Latin America Liver Cancer Market to grow at a CAGR of 5-11% over the period, 2015-2020. The market is currently valued at USD 35 million for the year 2015.

Liver cancer represents the fifth most commonly occurring cancer and the third leading reason for cancer related deaths in the world. Nearly 800,000 people are annually diagnosed with primary carcinoma. Therefore, the liver cancer medication market is anticipated to become an active ground for competition in the future. Nexavar (sorafenib) is the dominant therapeutic in the market, and is additionally the most important targeted medical aid that is regularly used for advanced-stage carcinoma patients.

With only a few approved drugs within the market and another few in the pipeline, it is a proven fact that incidence and mortality from the sickness continues to rise worldwide. Many new-targeted therapies are expected to enter the market in the following few years. Targeted cancer therapies use medication to prevent the expansion of cancer cells by interrupting certain molecules, known as molecular targets, thereby preventing the progression and growth of cancer cells. The treatment, also known as 'molecular targeted therapy', focuses on the cellular and molecular changes, pertaining specifically to cancer. It is thereby more effective, as compared to the other treatments for cancer, including radiotherapy and chemotherapy.

The Latin America liver cancer market is segmented based on:

- Type
- Primary
- Secondary
- Benign liver growths
- Diagnosis
- Ultrasound scans
- Confirmatory needle biopsy
- Endoscopic ultrasound
- Laparoscopy
- CT scan
- PET scan
- Magnetic resonance imaging (MRI) scans
- Therapeutics
- Hepatocellular carcinoma
- Cholangiocarcinoma
- Hepatoblastoma
- Targeted therapy
- Others
- End-User
- Pediatrics
- Adults
- Geography
- Argentina
- Brazil.

Some of the key participants in the industry include Bayer Schering Pharma AG, Onyx Pharmaceuticals, Inc., Celsion Corp., Alnylam Pharmaceuticals, Inc., ArQule, Inc., 4SC AG, ImClone Systems Inc., Jennerex Biotherapeutics, Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Etc.


- Increasing incidences of cancer
- Drug innovations with regard to the cancer
- Government initiatives
- Rise in aging populace
- Excessive alcohol consumptions
- High unmet needs for the treatment of liver cancer in the market
- Increasing health care expenditure


- Low success rate in clinical trials for cancer drugs
- Huge capital investments
- Low accessibility in remote areas
- Stringent regulatory procedures

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received
Note: Product cover images may vary from those shown
2 of 4


  • 4SC AG
  • Alnylam Pharmaceuticals
  • ArQule Inc.
  • Bayer Schering Pharma AG
  • F Hoffmann la- Roche
  • ImClone Systems Inc.
  • MORE
1. Executive Summary
2. Research Methodology
3. Introduction
3.1 Report Description
3.2 Markets Covered
4. Market Overview
4.1 Market Definition
4.2 Market Drivers
4.2.1 aging population
4.2.2 Rising Government and Non-Government Funding for Vaccine Development
4.2.3 high unmet needs for the treatment of liver cancer
4.2.4 excessive alcohol consumptions
4.3 Market Restraints
4.3.1 Techinical Advancements
4.3.2 Huge Capital Investments
4.3.3 Stringent Regulatory Procedures
4.3.4 Low success rate in clinical trails for cancer drugs
4.4 Market Opportunitites
4.5 Market Threats
5. Porters Five Force Analysis
5.1 Bargaining Power of suppliers
5.2 Bargaining power of buyers
5.3 Degree of competition
5.4 Threat of substitution
5.5 Threat of new entrants
6. Market Segmentation
6.1 By Type
6.1.1 primary liver cancer Hepatocellular carcinoma (HCC) Angiosarcoma Cholangiocarcinoma (bile duct cancer) Hepatoblastoma
6.1.2 secondary liver cancer
6.1.3 Benign liver growths
6.2 Diagnosis
6.2.1 ultrasound scans
6.2.2 Confirmatory Needle biopsy
6.2.3 Endoscopic Ultrasound
6.2.4 Laparoscopy
6.2.5 CT Scan
6.2.6 PET Scan
6.2.7 magnetic resonance imaging (MRI) scans
6.3 Therapeutics
6.3.1 Hepatocellular carcinoma
6.3.2 Cholangiocarcinoma
6.3.3 Hepatoblastoma
6.3.4 Targeted therapy
6.3.5 Others
6.4 By End User
6.4.1 Pediatrics
6.4.2 Adults
6.5 By Geography
6.5.1 Argentina
6.5.2 Brazil
7. Competitive Landscape
7.1 Mergers & Acquisitions
7.2 Agreements, Collaborations & Partnerships
7.3 New Product Launches
7.4 Recommendations to new market players
7.5 Value Chain Analysis
8. Company Profiles
8.1 Bayer Schering Pharma AG,
8.2 Onyx Pharmaceuticals, Inc., Celsion Corp.,
8.3 Alnylam Pharmaceuticals, Inc.,
8.4 ArQule, Inc.,
8.5 4SC AG,
8.6 ImClone Systems Inc.,
8.7 Jennerex Biotherapeutics, Inc.,
8.8 Pfizer Inc.,
8.9 F Hoffmann-La Roche Ltd..,
8.10 Bristol-Myers Squibb Company.
9. Appendix
9.1 Abbrevations
9.2 Sources
9.3 Bibliography
9.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4


4 of 4
Bayer Schering Pharma AG
Onyx Pharmaceuticals
Alnylam Pharmaceuticals
ArQule Inc.
ImClone Systems Inc.
Jennerex Biotherapeutics Inc.
Pfizer Inc.
F Hoffmann la- Roche
Bristol Myer Squibb Company
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown